We are live on
!
Find out more
Deerfield Management Portfolio holdings
AUM
$9.59B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter
Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.59B
AUM Growth
+$1.11B
(+13%)
Cap. Flow
-$1.32B
Cap. Flow
% of AUM
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$117M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$109M |
| 3 |
Boston Scientific
BSX
|
+$71.4M |
| 4 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$52M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$141M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$97.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$80.4M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
+$79.8M |
| 5 |
Enhabit
EHAB
|
+$66.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.76% |
| 2 | Miscellaneous | 16.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Savara
SVRA
$914M
| $83.6M | 0.87% |
13,569,000
| – | – |
2024 Q3
7 quarters
|
|
27
Lantheus
LNTH
$6.51B
| $83.5M | 0.87% |
752,999
-75,000
| -9% | -$6.99M |
2025 Q4
2 quarters
|
|
28
Syndax Pharmaceuticals
SNDX
$1.15B
| $82.6M | 0.86% |
3,779,900
| – | – |
2026 Q1
1 quarter
|
|
29
BioMarin Pharmaceuticals
BMRN
$10.6B
| $76.3M | 0.8% |
1,332,836
+481,280
| +57% | +$26.4M |
2026 Q1
1 quarter
|
|
30
Pfizer
PFE
$169B
| $73.2M | 0.76% |
3,040,000
| – | – |
2026 Q1
1 quarter
|
|
31
Indivior Pharmaceuticals
INDV
$3.83B
| $67.7M | 0.71% |
1,648,895
-1,448,895
| -47% | -$52.6M |
2024 Q3
7 quarters
|
|
32
Bio-Rad Laboratories Class A
BIO
$9.46B
| $66.4M | 0.69% |
226,070
| – | – |
2023 Q3
11 quarters
|
|
33
ARS Pharmaceuticals
SPRY
$400M
| $60.1M | 0.63% |
7,503,812
| – | – |
2022 Q4
14 quarters
|
|
34
Stoke Therapeutics
STOK
$1.56B
| $59.7M | 0.62% |
1,823,500
| – | – |
2025 Q4
2 quarters
|
|
35
Structure Therapeutics
GPCR
$1.5B
| $58.3M | 0.61% |
1,086,000
+318,007
| +41% | +$14.1M |
2023 Q1
13 quarters
|
|
36
Envista
NVST
$3.68B
| $58.2M | 0.61% |
2,210,100
| – | – |
2024 Q3
7 quarters
|
|
37
Inspire Medical Systems
INSP
$1.99B
| $57.9M | 0.6% |
1,296,862
-1,406,376
| -52% | -$66.7M |
2025 Q2
4 quarters
|
|
38
CareDx
CDNA
$3.31B
| $56.9M | 0.59% |
1,997,618
-193,382
| -9% | -$4.21M |
2025 Q3
3 quarters
|
|
|
39
Boston Scientific
BSX
$64.3B
| $56.1M | 0.59% |
+1,315,000
| New | +$71.4M |
2026 Q2
0 quarters
|
|
40
Belite Bio
BLTE
$5.75B
| $55M | 0.57% |
357,199
+53,186
| +17% | +$8.15M |
2025 Q4
2 quarters
|
|
|
PBLS
41
Parabilis Medicines Inc
PBLS
$2.81B
| $51.5M | 0.54% |
+1,880,704
| New | +$52M |
2026 Q2
0 quarters
|
|
42
Certara
CERT
$1.43B
| $49.2M | 0.51% |
7,512,928
-295,677
| -4% | -$1.67M |
2025 Q1
5 quarters
|
|
43
Disc Medicine
IRON
$2.18B
| $48.1M | 0.5% |
657,000
| – | – |
2023 Q2
12 quarters
|
|
44
BridgeBio Oncology
BBOT
$226M
| $37.2M | 0.39% |
4,885,446
| – | – |
2025 Q3
3 quarters
|
|
45
Tyra Biosciences
TYRA
$1.27B
| $32.5M | 0.34% |
1,017,000
+468,000
| +85% | +$15.5M |
2026 Q1
1 quarter
|
|
46
Monopar Therapeutics
MNPR
$465M
| $30M | 0.31% |
323,745
| – | – |
2025 Q3
3 quarters
|
|
47
Sionna Therapeutics
SION
$176M
| $30M | 0.31% |
680,916
-289,674
| -30% | -$11.6M |
2025 Q1
5 quarters
|
|
48
Avalyn Pharma
AVLN
$1.05B
| $24.1M | 0.25% |
+731,000
| New | +$21.1M |
2026 Q2
0 quarters
|
|
49
Foghorn Therapeutics
FHTX
$110M
| $21.4M | 0.22% |
4,394,367
| – | – |
2024 Q2
8 quarters
|
|
50
Beta Bionics
BBNX
$882M
| $20.7M | 0.22% |
1,324,000
| – | – |
2025 Q1
5 quarters
|
|
Similar funds
GGHC
SC
Deerfield Management's Q2 2026 Portfolio in Review
As of Q2 2026, Deerfield Management held 94 positions worth $9.59B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.
Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.
- Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
- Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
- Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
- Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
- Deerfield Management's ten largest holdings make up 53% of its $9.59B portfolio in Q2 2026.
- Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.59B.
Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.